论文部分内容阅读
目的探讨依达拉奉对急性重型颅脑损伤的治疗作用及安全性。方法将60例患者随机分为2组,依达拉奉组30例:常规治疗基础上加用依达拉奉30mg稀释后30min内静滴注完,1次/12h连续10天。对照组30例常规治疗不给予脑保护。结果给药组伤后10天内颅内压显著升高和重度脑水肿者比例均较对照组明显减少。结论早期应用依达拉奉治疗急性重型颅脑损伤可以降低患者的颅内压升高的幅度,缩短昏迷时间促进患者神经功能恢复,降低伤残率,改善预后安全可靠。
Objective To investigate the therapeutic effect and safety of edaravone on acute severe craniocerebral injury. Methods Sixty patients were randomly divided into two groups: edaravone group of 30 patients: intravenous infusion of 30mg diluted edaravone 30min after intravenous infusion, once / 12h for 10 consecutive days. Control group, 30 cases of routine treatment did not give brain protection. Results Within 10 days after injury, the intracranial pressure and the percentage of severe cerebral edema in the treated group were significantly decreased compared with the control group. Conclusion The early application of edaravone in patients with acute severe craniocerebral injury can reduce the magnitude of intracranial pressure in patients with shortened coma time to promote neurological recovery, reduce disability and improve the prognosis of the safe and reliable.